Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Stifel Financial Corp

Stifel Financial Corp boosted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 126.3% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 17,121 shares of the biopharmaceutical company’s stock after purchasing an additional 9,555 shares during the quarter. Stifel Financial Corp’s holdings in Halozyme Therapeutics were worth $980,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in HALO. International Assets Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $33,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in Halozyme Therapeutics during the second quarter worth $49,000. GAMMA Investing LLC grew its holdings in Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 350 shares during the last quarter. Toth Financial Advisory Corp purchased a new position in shares of Halozyme Therapeutics in the third quarter valued at $57,000. Finally, FSC Wealth Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the 3rd quarter worth $65,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $68.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, December 18th. Wells Fargo & Company cut shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price objective for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price objective for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Finally, JMP Securities boosted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.11.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $47.16 on Tuesday. The stock has a fifty day moving average price of $50.77 and a 200 day moving average price of $54.15. Halozyme Therapeutics, Inc. has a 52 week low of $33.15 and a 52 week high of $65.53. The firm has a market capitalization of $6.00 billion, a P/E ratio of 15.62, a PEG ratio of 0.43 and a beta of 1.23. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32.

Insider Activity

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total value of $532,600.00. Following the transaction, the senior vice president now owns 173,756 shares in the company, valued at $9,254,244.56. This trade represents a 5.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 30,000 shares of company stock valued at $1,621,800 in the last 90 days. 2.70% of the stock is currently owned by insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.